#United States #Cranbury #T-Cell Therapy #Porton Advanced #Eureka Therapeutics

Porton Advanced and Eureka Therapeutics Join Forces

On March 19, 2025, Porton Advanced, a prominent player in contract development and manufacturing for advanced therapy medicinal products (ATMPs), announced its collaboration with Eureka Therapeutics, an emerging biotechnology firm based in the San Francisco Bay Area. This partnership aims at accelerating the development of innovative T-cell therapies targeted at both solid tumors and hematologic cancers.

Eureka Therapeutics is renowned for its groundbreaking platforms, the proprietary ARTEMIS® cell receptor and E‑ALPHA® antibody discovery systems, which are utilized to create safer and more effective T-cell therapies. By teaming up with Porton Advanced, they intend to harness the extensive capabilities of Porton’s state-of-the-art manufacturing facilities to drive global clinical development forward.

Oliver Ju, Chairman of Porton Advanced, expressed enthusiasm regarding the new alliance. He emphasized that the successful completion of the initial phase of their collaborative program reflects the operational excellence of the Porton team. Ju stated, “Our ongoing collaboration will utilize our flexible manufacturing models and cutting-edge technologies to expedite the advancement of transformative therapies.”

Echoing this sentiment, Dr. Cheng Liu, Founder and CEO of Eureka Therapeutics, expressed confidence in the partnership's potential to expedite their critical pipeline programs. He noted that Porton's robust manufacturing capabilities provide a solid foundation to support Eureka's innovative endeavors effectively.

Accelerating Development of Advanced Therapies

With the successful establishment of technology, Porton Advanced is set to support Eureka Therapeutics in conducting Investigator-Initiated Trials (IITs) through its CAR-T manufacturing services, which adhere to rigorous quality standards. These trials are crucial for generating vital data to meet clinical milestones and further propel Eureka's creative T-cell therapy projects.

Porton Advanced boasts a strong track record, having successfully backed over 60 ATMP Clinical, Investigational New Drug (IND), and IIT projects within China. The company has completed over 140 IIT batches, maintaining a flawless release success rate. This success highlights Porton Advanced's capability to meet stringent quality manufacturing expectations while facilitating groundbreaking advancements in the biotech sector.

By collaborating closely, both companies are strategically positioned to facilitate the advancement of innovative therapies on a global scale. Porton Advanced's commitment to its clients is underscored by its focus on customer-centric service, aiming to revolutionize drug development processes and bring effective treatment options to the public sooner.

About the Companies

Porton Advanced is a subsidiary of Porton Pharma Solutions, headquartered in Cranbury, New Jersey, with two cGMP-certified facilities located in Suzhou, China. This positioning allows Porton Advanced to provide a spectrum of services encompassing cell banking, process development, and cGMP production. Its facilities span 215,000 square feet, housing advanced production lines and therapy suites to support various stages of drug development—from early research to commercialization.

Eureka Therapeutics, focused on finding transformative T-cell therapies for patients with cancer, is utilizing innovative approaches to develop its therapies further. This collaboration between two industry leaders showcases a promising future for T-cell therapies and demonstrates the potential for improved treatment options for patients worldwide.

In summary, the partnership between Porton Advanced and Eureka Therapeutics is a decisive step forward in the quest for advanced therapies, with the capabilities of both organizations merging to expedite developments that have the potential to alter the landscape of cancer treatment.